| Size | Price | Stock | Qty |
|---|---|---|---|
| 1g |
|
||
| 2g |
|
||
| 5g |
|
||
| 10g |
|
||
| 25g |
|
||
| Other Sizes |
|
Inosine pranobex (Imunovir; Delimmun; Groprinosin), a combinatinon of inosine, acetamidobenzoic acid, and dimethylaminoisopropanol, is a novel, potent, broad-spectrum antiviral agent potentially useful for HIV/AIDs infection. Inosine pranobex is also an immunopotentiator/immunostimulant, and has no direct effect on viral cells.
| ADME/Pharmacokinetics |
Absorption, Distribution and Excretion
Rapidly absorbed from GIT Via urine Biological Half-Life 50 min |
|---|---|
| References | |
| Additional Infomation |
Inosine pranobex (Isoprinosine or Methisoprinol) is a combination of inosine, acetamidobenzoic acid, and dimethylaminoisopropanol used as an antiviral drug.
Inosine Pranobex is a formulation containing inosine, 4-acetamidobenzoic Acid, and N,N-dimethylaminoisopropanol, with immunomodulatory and antiviral activities. Although the exact mechanism of action is unknown, inosine pranobex appears to act as a thymus hormone analog; following administration, this agent may both induce T-cell differentiation and potentiate lymphoproliferative responses against transformed or virally-infected cells. An alkylamino-alcohol complex of inosine used in the treatment of a variety of viral infections. Unlike other antiviral agents, it acts by modifying or stimulating cell-mediated immune processes rather than acting on the virus directly. Drug Indication Inosine pranobex is also indicated for mucocutaneous infections due to herpes simplex virus (type 1 and type II) and for treatment of genital warts as adjunctive therapy to podophyllin or carbon dioxide laser. Mechanism of Action Inosine pranobex stimulates cell-mediated immune processes to viral infections. Pharmacodynamics Works by slowing the growth and spread of the virus in the body. It may also stimulate the immune system in the body, which helps to increase the body's ability to fight these infections. |
| Molecular Formula |
C52H78N10O17
|
|---|---|
| Molecular Weight |
1115.23
|
| Exact Mass |
1114.554
|
| Elemental Analysis |
C, 56.00; H, 7.05; N, 12.56; O, 24.39
|
| CAS # |
36703-88-5
|
| Related CAS # |
36703-88-5 (pranobex);141684-35-7 (phosphoramidite);58-63-9;
|
| PubChem CID |
135449284
|
| Appearance |
White to off-white solid powder
|
| Boiling Point |
732.8ºC at 760 mmHg
|
| Flash Point |
397ºC
|
| LogP |
1.766
|
| Hydrogen Bond Donor Count |
13
|
| Hydrogen Bond Acceptor Count |
22
|
| Rotatable Bond Count |
14
|
| Heavy Atom Count |
79
|
| Complexity |
658
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
O1[C@]([H])(C([H])([H])O[H])[C@]([H])([C@]([H])([C@]1([H])N1C([H])=NC2C(N([H])C([H])=NC1=2)=O)O[H])O[H].O([H])C([H])(C([H])([H])[H])C([H])([H])N(C([H])([H])[H])C([H])([H])[H].O([H])C([H])(C([H])([H])[H])C([H])([H])N(C([H])([H])[H])C([H])([H])[H].O([H])C([H])(C([H])([H])[H])C([H])([H])N(C([H])([H])[H])C([H])([H])[H].O([H])C(C1C([H])=C([H])C(=C([H])C=1[H])N([H])C(C([H])([H])[H])=O)=O.O([H])C(C1C([H])=C([H])C(=C([H])C=1[H])N([H])C(C([H])([H])[H])=O)=O.O([H])C(C1C([H])=C([H])C(=C([H])C=1[H])N([H])C(C([H])([H])[H])=O)=O
|
| InChi Key |
YLDCUKJMEKGGFI-QCSRICIXSA-N
|
| InChi Code |
InChI=1S/C10H12N4O5.3C9H9NO3.3C5H13NO/c15-1-4-6(16)7(17)10(19-4)14-3-13-5-8(14)11-2-12-9(5)18;3*1-6(11)10-8-4-2-7(3-5-8)9(12)13;3*1-5(7)4-6(2)3/h2-4,6-7,10,15-17H,1H2,(H,11,12,18);3*2-5H,1H3,(H,10,11)(H,12,13);3*5,7H,4H2,1-3H3/t4-,6-,7-,10-;;;;;;/m1....../s1
|
| Chemical Name |
4-acetamidobenzoic acid compound with 9-((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-1,9-dihydro-6H-purin-6-one and 1-(dimethylamino)propan-2-ol (3:1:3)
|
| Synonyms |
Inosine pranobex; NP113; NP-113; NP 113
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~62.5 mg/mL (~56.04 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (1.87 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (1.87 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (1.87 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.8967 mL | 4.4834 mL | 8.9668 mL | |
| 5 mM | 0.1793 mL | 0.8967 mL | 1.7934 mL | |
| 10 mM | 0.0897 mL | 0.4483 mL | 0.8967 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
